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BRAF  - v-raf murine sarcoma viral oncogene homolog B 
CI  - Confidence interval 
CIMP  - CpG island methylator phenotype 
CIN  - Chromosomal instability 
CpG  - Cytosine-phosphate-Guanine 
CRC  - Colorectal cancer 
DNA  - Deoxyribonucleic acid 
FOBT  - Faecal occult blood test 
HR  - Hazard ratio 
ICER  - Incremental cost-effectiveness ratio 
MEI  - Magnetic endoscopic imaging 
MLH1  - MutL Homolog 1 
MMR  - Mismatch repair 
MSI  - Microsatellite instability 
MSS  - Microsatellite stable 
NORCCAP - Norwegian Colorectal Cancer Prevention trial 
NordICC - Nordic-European Initiative on Colorectal Cancer 
PLCO  -  Prostate, Lung, Colorectal and Ovarian cancer screening trial 
RR  - Rate ratio 
SCORE - Screening colon rectum 
SSA/P  - Sessile serrated adenoma/polyp 
TSA  - Traditional serrated adenoma 
UK  - United Kingdom 
US  - United States of America 
WHO  - World Health Organization 
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Colorectal cancer (CRC) is the third most common cancer in the world1  and the second 
most common cancer in Norway (figure 1).2 About 3,800 Norwegians are diagnosed with 
CRC each year, and approximately 1,600 die from the disease.3 Mortality rates have been 
quite stable the last 50 years, but incidence rates in Norway have been steadily increasing 
(figure 2).2 The reason for this incline in CRC incidence is unknown. 
 
 
 
Figure 1: Estimated numbers of the 10 most frequent cancers except non-melanoma skin 
cancers in Norway (2012).2 
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Figure 2: Time trends in Norway for colorectal cancer incidence and mortality in men 
and women.1 Rates are age-standardized per 100,000 person-years. 
 
Known risk-factors for CRC are increasing age, male sex, inflammatory bowel disease, 
prior personal history of CRC or adenomas, first-degree relatives with CRC, a diet high in 
fat or low in fiber, calcium or both, smoking, high alcohol consumption, sedentary 
lifestyle and some genetic disorders.4,5 Regular use of aspirin, non-steroidal anti-
inflammatory drugs and the use of hormone-replacement therapy have been suggested as 
protective factors.4 Because CRC is considered a major health burden, screening for CRC 
has been implemented in many countries.6,7  
According to the World Health Organization (WHO), screening is “…the presumptive 
identification of unrecognized disease or defect by the application of tests, examinations 
or other procedures…”.8 The WHO lists a number of prerequisites which should be met 
for a disease to be suitable for screening, including:  
• The disease should be an important health problem  
• Treatment for the disease should be accepted  
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• The natural history of the disease should be adequately understood  
• There should be a recognizable latent or early symptomatic stage 
•  There should be a suitable test or examination 
• The test should be acceptable to the population 
For CRC, all criteria concerning the disease are met: CRC is frequent in the population 
(the lifetime risk in the general population is about 5%),   treatment most often involves a 
surgical procedure, and most CRC cases develop from benign precursors; adenomas, 
which may be detected endoscopically.  The present thesis investigates whether flexible 
sigmoidoscopy is a suitable and acceptable colorectal cancer screening test. 
The association between colorectal cancer and adenomas has been known for a long 
time,9 and the development from adenoma to carcinoma (adenoma-carcinoma sequence 
theory) was described further by Muto in 1975.10 In 1988, Vogelstein proposed that this 
sequence was a result of a series of DNA mutations.11 That CRCs may bleed and that this 
blood can be detected in stool was known already in the 18th century, but detection of 
faecal occult blood was not feasible as a mass-screening method until the 1960s when a 
guaiac-based kit for use at patients’ home was introduced.12 
The first large randomized controlled trial of screening for faecal occult blood to reduce 
mortality and incidence of colorectal cancer was launched in the United States in 1975. 13 
Soon thereafter, researchers in several European countries initiated three randomized 
trials comparing screening with biennial faecal occult blood test (FOBT) to no screening. 
These studies found that screening with FOBT biennially or annually reduce mortality 
from colorectal cancer by 15-33%.13-16 It was, however, evident from meta-analyses of 
these trials that FOBT did not reduce incidence of CRC. 17,18 
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Screening may reduce the burden of CRC in two different ways, by early detection or by 
prevention (figure 3). 
 
Figure 3: How screening works. Screening may reduce the burden of CRC in two 
different ways; by prevention (detection, and removal, of precursor lesions to avoid 
development of the disease) and by early detection (detection of the disease in a stage 
with favorable prognosis). 
 
The prognosis of CRC is closely related to disease stage at diagnosis.19 By detecting CRC 
at an early stage, treatment might be curable and mortality might be reduced. Detecting 
CRC earlier, however, will not reduce incidence.  FOBT is an early-detection test, that is, 
a test that only detects the disease (a tumor which has already become malignant). The 
abovementioned randomized controlled trials used guaiac-based FOBT’s. This test has a 
sensitivity for CRC precursors (advanced adenomas) of 11-25%,4 which explains the lack 
of effectiveness on CRC incidence. It should be noted that one of the FOBT trials, the 
Minnesota trial, showed an effect on CRC incidence, but in this trial, 38% of participants 
screening annually and 28% of those screened biennially had a colonoscopy13 compared 
to less than 10% in the other three FOBT trials.14-16 During colonoscopy, adenomas may 
be detected and removed. 
Screening may reduce CRC incidence (and as a consequence also mortality) by disease 
prevention if the applied test is able to detect benign CRC precursors (adenomas). In 
1974, Gilbertsen published a report of 18 000 patients from Minnesota who had periodic 
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examinations with a rigid proctosigmoidoscope.20 If adenomas were detected during the 
examination, they were removed. After 25 years, the numbers of distal colorectal cancers 
in these patients were 85% lower than in the background population of Minnesota, 
suggesting the possibility that screening with excision of adenomas would reduce 
incidence of CRC, and subsequently mortality from CRC. Several subsequent case-
control studies supported this finding.21,22  
The introduction of flexible endoscopes made the examination easier for the endoscopist 
and less uncomfortable for the patient, and a great technological breakthrough was 
achieved in the 1980s with the introduction of the videoendoscope which allowed the 
endoscopic image to be displayed on a screen beside the examination table.23 
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Endoscopy with flexible endosscopes was introduced in the 1960s.24 Sigmoidoscopy is 
the visual inspection of the mucosa of the rectum and the distal colon (sigmoid colon and 
sometimes including the descending colon). The flexible endoscope used for the 
examination has a working channel, which allows introduction of instruments for both 
diagnostic and therapeutic procedures. Flexible sigmoidoscopy has several advantages: It 
takes on average less than 10 minutes to complete the procedure, only an enema is 
required for bowel cleansing, can be performed without sedation, is well accepted by 
patients and entails a low rate of serious complications.25-27. 
The most important shortcoming of flexible sigmoidoscopy is that only the distal part of 
the colorectum is examined. About 60% of CRC cases arise in this part of the colon,28 
which means that 40% of CRC cases develops in the part of the colon beyond the reach of 
a sigmoidoscope (proximal colon). To detect advanced neoplasia (CRC or adenomas with 
diameter 10 mm or larger, with villous histology or high-grade dysplasia) in the proximal 
colon, patients may be referred for colonoscopy if an adenoma is detected at flexible 
sigmoidoscopy. Whether individuals with any adenoma or only those with advanced 
adenomas (adenomas with diameter 10 mm or larger, with villous histology or high-grade 
dysplasia) should be offered colonoscopy has been debated29 and is important both with 
regard to costs and risk of complications. In one study of individuals with one or more 
adenomas detected in the rectosigmoid, a higher prevalence of synchronous proximal 
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advanced neoplasia was found than in individuals without distal adenomas, irrespective of 
the characteristic of the distal adenoma.30 Another study found that only individuals with 
advanced distal adenomas have a higher prevalence of proximal advanced neoplasia 
compared to individuals without adenomas in the rectosigmoid.31 As a consequence of 
this uncertainty, randomized controlled trials of flexible sigmoidoscopy screening have 
applied different criteria for colonoscopy-referral after the screening examination.32-35 
However, even with normal findings at flexible sigmoidoscopy, some individuals will 
have a proximal advanced neoplasia: About 50% of individuals with proximal advanced 
neoplasia don’t have a distal adenoma.30,36  
A recent study showed that also about 50% of proximal serrated polyps (another type of 
polyp which may be CRC precursor, see section 1.3) did not have a distal polyp 
(adenoma or serrated)  that could trigger a full colonoscopy, 37 further adding to the 
limitation of flexible sigmoidoscopy as a cancer prevention tool. 
The effectiveness of flexible sigmoidoscopy- and FOBT-screening on CRC mortality has 
never been directly compared in randomized controlled trials. In a Cochrane-review, the 
two tests were indirectly compared in a multiple-treatment meta-analysis.18 The risk of 
dying from CRC was 15% lower with flexible sigmoidoscopy screening compared to 
annual or biennial FOBT-screening (guaiac-based tests), but the difference was not 
statistically significant (relative risk 0.85, 95% Credibility Interval 0.71-1.01). In Norway, 
a screening pilot trial has been launched which directly compares flexible sigmoidoscopy 
to biennial FOBT (immunochemical test). In this trial, 140,000 individuals aged 50-74 
years will be randomized to be invited to flexible sigmoidoscopy or biennial FOBT.38 
Colonoscopy with complete examination of the colorectal mucosa has the ability to 
overcome the inherent shortcoming of flexible sigmoidoscopy. In the US, colonoscopy is 
the most common screening test.39 Evidence for colonoscopy as a screening tool is 
however derived from flexible sigmoidoscopy screening trials and observational studies 
which do not take into account complications and compliance with screening. There are 
several large ongoing randomized controlled trials that evaluate the effectiveness of 
colonoscopy screening on colorectal cancer incidence and mortality.40-43 
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The first randomized controlled trial of flexible sigmoidoscopy screening versus no 
screening was launched in Telemark County, Norway, in 1983. This small study included 
only 799 patients randomized to flexible sigmoidoscopy screening or no screening, but 
with a high compliance rate of 81%. After 13 years, CRC incidence was reduced by 80% 
in an intention-to-treat analysis.44 In the1990s, large randomized controlled trials of 
screening sigmoidoscopy versus no screening were initiated in the United Kingdom, Italy, 
the United States, and Norway. 32,33,45,46 Long-term follow-up results have been published 
from the first three trials,32-34 and short term follow-up of part of the trial cohort in the 
Norwegian (NORCCAP – Norwegian Colorectal Cancer Prevention) trial.45 Long-term 
follow-up in the NORCCAP trial is part of this PhD thesis and will be discussed in detail 
later (paper I).35 The results from the three previous trials were consistent in reduction of 
CRC incidence (18% - 23%) and CRC mortality (22% - 31%).32-34 A distinguished 
feature of the NORCCAP trial lies in the design of the trial. While participants in 
NORCCAP were randomized directly from the population registry (post-randomization 
consent), the three other flexible sigmoidoscopy trials recruited volunteers (pre-
randomization consent). This might have resulted in estimates that do not reflect the 
effect of the screening intervention in the entire population.  Further advantages of the 
NORCCAP trial are inclusion of a younger age-cohort (50-54 years) than the other trials, 
and the absence of contamination by concurrent CRC screening outside the trial. 
Screening as indication for colonoscopy is infrequent in Norway.47 
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For many years, the most common polyps of the large intestine were divided into two 
main categories; adenomas and hyperplastic polyps. Hyperplastic polyps were considered 
to have no malignant potential, and adenomas were considered to be the only precursors 
to CRC.48 But there were reports which were not compatible with this theory: 
Hyperplastic polyps were found more frequently in individuals with CRC compared to 
those without CRC.49 Cases were described with CRC occurring in polyps with mixed 
hyperplastic and adenomatous morphology,50 and large hyperplastic polyps were 
described, indicating the potential of growth.51 In 1996, Torlakovic and coworkers 
described increased risk for CRC in individuals with so called hyperplastic polyposis 
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(multiple large hyperplastic polyps), and found morphologic features which distinguished 
hyperplastic polyps in polyposis patients from diminutive hyperplastic polyps found in 
patients without hyperplastic polyposis.52 In 2003, Goldstein published a histologic 
analysis of a series of lesions diagnosed as hyperplastic polyps in patients who later 
developed CRC in the same anatomic bowel segment.53 These polyps were 
morphologically identical to the polyps described by Torlakovic and suggested that also 
non-adenomatous polyps could be precursors for CRC.  
Today, the type of polyps Torlakovic and Goldstein described is known as sessile serrated 
adenoma/polyp (SSA/P). They are a subtype of a group of polyps called serrated polyps, 
which in addition to SSA/P consists of hyperplastic polyps and the rare traditional 
serrated adenomas (TSA).54  
There are three established molecular CRC pathways; 
• the chromosomal instability pathway (CIN),55  
• the microsatellite instability pathway (MSI)56   
• the CpG island methylator phenotype pathway (CIMP), also called the serrated 
pathway.57  
A tumor may exhibit features from more than one of these pathways.55 About 70-80% of 
CRC cases develop from adenomas, mostly through the CIN pathway which is 
characterized by imbalance in chromosome number and loss of heterozygocity.55 
Adenomas are thought to be the precursor of CRC with CIN. MSI is characterized by loss 
of DNA mismatch repair activity. About 15% of CRC exhibit MSI which may be caused 
by either germ-line mutation in one or several of the mismatch repair (MMR) genes 
(Lynch syndrome), or by hypermethylation of the promoter region of the MLH1 gene (an 
MMR gene).56 Hypermethylation of CpG islands (CIMP-high) is the key feature of 
tumors of the serrated pathway. CpG islands (repetitive sequences of cytosine and 
guanosine nucleotides) are found in promoter regions of about half of all genes. Aberrant 
hypermethylation of these regions may silence the downstream gene. CIMP may lead to 
CRC by methylation of the promoter region of MLH1, causing CIMP-high MSI tumors, 
or by silencing tumor suppressor genes, causing CIMP-high microsatellite stable (MSS) 
tumors.56,57 
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CIMP is found in both adenomas58 and serrated polyps,59 but more frequently in the latter. 
BRAF-mutations (often found in CIMP high tumors) are found in serrated polyps, but 
seldom  in adenomas.58,59 Thus, on this basis, serrated polyps (and in particular SSA/P) 
are thought to be the main precursors of CIMP-high CRC.  
Little is known about the natural history of serrated polyps, but SSA/P is now believed to 
be a CRC precursor, and excision of these lesions is recommended in updated guidelines 
and a consensus statement both in the US and in Europe. 60-62 However, these guidelines 
acknowledge that the recommendations are based on low-quality evidence, and further 
research is warranted. 
At the time the NORCCAP trial was conducted, all non-adenomatous polyps were 
diagnosed as hyperplastic polyps (WHO criteria of 2000) and were not considered to be 
CRC precursors. Thus, patients with these polyps were not recommended surveillance 
according to the Norwegian postpolypectomy guidelines (the surveillance guidelines used 
in NORCCAP).63 In addition, the treatment of polyps which macroscopically appeared to 
be non-adenomatous was not uniform in NORCCAP. Some were removed by endoscopic 
polypectomy, and some were left in-situ after biopsy suggested non-adenomatous 
histology. This gave us the opportunity to study the natural history of serrated polyps. The 
NORCCAP trial also gave us the opportunity to assess the risk of CRC in individuals 
with serrated polyps compared to individuals with other kind of polyps detected at 
screening (paper II).64 
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Colonoscopy (with polypectomy if appropriate) is the cornerstone for investigation of any 
positive CRC screening test. As screening involves examination of asymptomatic, and 
most often healthy, individuals, it is particularly important to avoid complications and 
discomfort. If the screening procedure (including colonoscopy) is considered to be 
uncomfortable, it may affect screening compliance.  
Colonoscopy may be an uncomfortable and even painful procedure.65,66 Several methods 
to reduce colonoscopy discomfort have been introduced, including thinner endoscopes, 
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endoscopes with variable stiffness, carbon dioxide insufflation and installation of water 
during insertion.67-70 
Pain during colonoscopy is caused by stretching of the mesentery, which is caused by 
looping of the instrument, most often when the sigmoid colon is negotiated.71 The 
endoscopist is often unaware of the type of looping that has occurred.72 To avoid looping 
of the instrument, and to facilitate correct maneuvers to un-loop the endoscope, and 
thereby reduce pain, external imaging of the endoscope’s configuration within the 
abdomen might reduce patient’s discomfort. 
In the beginning of the endoscopy-era, colonoscopy without the aid of fluoroscopy (the 
use of x-ray to visualize the intraabdominal position of the endoscope) was not 
considered appropriate,24 but as technique improved, many colonoscopists abandoned 
fluoroscopy. Radiation exposure and large investment costs and thus inaccessibility were 
important arguments in a US survey of why endoscopists did not use fluoroscopy.73 In 
Norway, however, fluoroscopy has been widely accepted as an important aid in difficult 
colonoscopies and is available in many endoscopy units throughout the country. 
Unfortunately, the view of the abdomen is limited, and due to radiation hazard, 
fluoroscopy should only be used a few seconds at a time.  
In 1993, a three-dimensional magnetic endoscopic imaging system (MEI) as an 
alternative to fluoroscopy was described.74 This system allows a continuous view of the 
position of the endoscope during the entire examination without any radiation hazard. 
MEI was shown to improve caecum intubation rate75,76 and shorten time to reach the 
caecum75 in prospective trials compared to colonoscopy without any external imaging, 
but the effect of MEI on patient’s discomfort was inconsistent.75-79 Further, the MEI is 
expensive, and before new devices are introduced in clinical practice, it should be tested 
against the best existing equipment. Colonoscopy with MEI has not been compared to 
colonoscopy with the aid of fluoroscopy. It is therefore unknown if colonoscopy 
performance improves with the addition of MEI in endoscopy units who already have 
access to fluoroscopy. In paper III, we report results from a randomized controlled trial, 
comparing MEI-aided colonoscopy to colonoscopy with fluoroscopy on-demand.80  
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CRC is a common malignancy. Due to its detectable precursor state, the disease may be 
preventable. If a national CRC screening program is implemented in Norway, all healthy 
individuals in the targeted age-range will be invited for screening. Many individuals will 
be referred for colonoscopy (or colonoscopy may be chosen as the primary screening 
test), and methods to reduce discomfort should be investigated. It is important to provide 
policy-makers with high-quality evidence from randomized controlled trials to guide 
decision-making on screening and whether investment in new equipment should be 
performed. The reports from the NORCCAP trial and the magnetic imager trial included 
in this thesis provide such evidence. In recent years, it has become evident that there are 
several types of polyps that may be CRC precursors and which may be detected through 
screening. Much is unknown about these serrated polyps, and evidence from prospective 
trials is scarce. In the following sections, I will provide results from analyses and follow-
up of individuals with large serrated polyps identified in the NORCCAP trial. 
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The thesis “Flexible sigmoidoscopy screening for colorectal cancer” investigates 
flexible sigmoidoscopy as a screening tool for colorectal cancer in a broad sense. 
  
Specifically, the aims of this thesis are: 
1. To investigate the long-term effect of flexible sigmoidoscopy screening on 
colorectal cancer incidence and mortality in a population-based randomized 
controlled trial 
2. To investigate the risk of CRC in individuals with large, serrated polyps detected 
at  flexible sigmoidoscopy screening. 
3. To investigate whether colonoscopy with the aid of a magnetic endoscopic 
imaging system is less uncomfortable than standard colonoscopy with fluoroscopy 
on-demand in a randomized controlled trial 
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In November 1998, individuals aged 55-64 years living in the city of Oslo or Telemark 
County (figure 4) were identified through the Population Registry and were eligible for 
the study. An equal number of men and women 
born between 1935 and 1945 were randomly 
sampled to be invited for screening (screening 
arm).81  After sampling, these individuals were 
randomized 1:1 to receive an invitation for once 
only flexible sigmoidoscopy screening or to a 
combination of once only flexible sigmoidoscopy 
screening and faecal occult blood testing (FOBT) 
(figure 5). An independent body (IBM Norway) 
performed both randomization procedures using 
computer-based algorithms. The remaining 
individuals in the same age-group in the screening 
areas served as controls (control arm). Controls 
were unaware of their status as participants in the 
study and were not offered any intervention.  
Figure 4: The screening trial 
was conducted in Oslo city and 
Telemark County 
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Based on data from the Norwegian Cancer Registry, there was an expected accumulated 
CRC incidence of 1% during a 5 year period (180 cases per 100,000 person years) in the 
60-69 years age group. Assuming 70% compliance to detect a 30% reduction in CRC 
incidence (intention-to-treat analysis) after 5 years with 90% power and a significance 
level of 5%, 14,000 individuals had to be included in the screening arm and 42,000 in the 
control arm.45 At the end of the year 2000, the funding bodies (Norwegian Government 
and the Norwegian Cancer Society) decided to expand the trial and also include 
individuals aged 50-54 years (born 1946-1950) in the trial. The rationale for this 
extension was to obtain more information about the ideal age to start screening. No 
separate power calculation was conducted for this extension of the trial. The random 
sampling from the Population Registry and randomization to screening with flexible 
sigmoidoscopy or flexible sigmoidoscopy + FOBT was done by IBM Norway in the same 
way as for the 55-64 year age-group. The trial was registered at ClinicalTrials, identifier 
NCT00119912 (available at http://www.clinicaltrials.gov).  
All individuals in the trial were assigned a personal study entry date into the trial. For the 
individuals in the screening arm, this was the date for their proposed examination date in 
the invitation letter. Individuals in the control arm were assigned an entry date evenly 
distributed between January 1st 1999 and December 31st 2000 for controls in the 55-64 
year age-group, and between January 1st and December 31st 2001 for the 50-54 year age-
group. The only exclusion criterion in the trial was a personal history of CRC before 
Figure 5: Flow 
chart of the 
NORCCAP 
screening trial 
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study entry. As randomization was done up to two years before invitation (date of 
invitation served as study entry date), individuals who died, were diagnosed with CRC or 
emigrated before individual study entry were excluded from the analyses (figure 5). The 
number of individuals included in the screening group (50-54 year age-group) was 
restricted by the capacity of the screening centers. Due to higher birth rates after world 
war II, the screening:control ratio was 1:5.4 in the 50-54 year age-group (born 1946-
1950) compared to 1:3 in the 55-64 year age-group. As the population number in Oslo 
was higher than in Telemark, the screening:control ratio was 1:6.1 in Oslo and 1:1.5 in 
Telemark, see table 1. 
 
 
 
 
Table 1: Number of individuals included in the screening group and control group by 
age-group and screening center. 
 
 
 
 
 

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Individuals in the screening arm were invited for screening by mail. Individuals were 
excluded from the examination, but included in the intention to treat analysis, if they met 
any of the predefined exclusion criteria. These were: 1) Previous open colorectal surgery, 
2) Need for long term attention and nursing services, 3) Ongoing cytotoxic treatment or 
radiotherapy for malignant disease, 4) Severe chronic cardiac or pulmonary disease, 5) 
Patients with heart valve replacement on lifelong anticoagulant treatment, 6) Admission 
 55-64 years  50-54 years 
 Screening group Control group  Screening group Control group 
Telemark 6,847 6,868  3,467 8,308 
Oslo 6,805 34,221  3,453 28,823 
Total 13,652 41,089  6,920 37,131 
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to hospital for a coronary event during the previous three months, 7) Cerebrovascular 
accident during the previous three months, and 8) Residence abroad. 
 
Individuals in the screening arm were invited to once only flexible sigmoidsocopy 
screening or a combination of once only flexible sigmoidoscopy and once-only FOBT. 
The FOBT kit (FlexSure OBT®, Beckman-Coulter, Palo Alto, CA, USA) was sent by 
mail, and individuals were asked to complete one sample from three consecutive stools 
and to deliver the tests on arrival at the screening examination. There were no dietary 
restrictions. FlexSure OBT is a qualitative immunochemical faecal occult blood test, and 
the tests were analyzed by the endoscopy nurse at the screening center before the 
endoscopic examination. Choosing only the FOBT was not an option.  
The flexible sigmoidoscopy screening examinations were conducted at two screening 
centers, one in each of the two trial areas (city of Oslo, Porsgrunn in Telemark County). 
In addition, a temporary screening unit was established at Rjukan hospital in the most 
rural parts of Telemark for four weeks each year (1999-2001), to screen the population in 
these most remote parts of the screening area. This center was staffed by the same 
endoscopists and endoscopy nurses as the main screening center in Telemark.  
 
Ordinary colonoscopes were used for both the screening flexible sigmoidoscopy and 
endoscopic work-up (140 cm Olympus colonoscopes, Olympus Europa GmbH, Hamburg, 
Germany) except from the temporary established screening unit (Rjukan) at which a 
disposable endoscopy sheath system was used (Endosheath®, Vision Sciences, Natick, 
MA, USA).82 
 
Bowel cleansing was limited to a 240 ml sorbitol enema given at the screening center 
prior to the examination. During the flexible sigmoidoscopy, all detected lesions were 
biopsied and sent for histopathological examination. A positive screening test was defined 
as any polyp 10 mm or larger, any histologically verified adenoma, carcinoma or a 
positive FOBT. All persons with a positive screening examination were referred for 
colonoscopy. During colonoscopy, all detected adenomas were removed and retrieved for 
histopathological examinations. Treatment of non-adenomatous polyps was by the 
discretion of the endoscopist: Most were removed by polypectomy, while some were 
biopsied only. Specimens were examined by dedicated and trained pathologists: 
Workshops were held for the participating pathologists to ensure conformity in diagnosis, 
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and a referent pathologist performed blinded revision of a sample of retrieved 
specimens.81  When the colorectum was considered free of all lesions (with the exceptions 
mentioned above), individuals with the following conditions were advised to have a 
surveillance colonoscopy according to Norwegian postpolypectomy guidelines. A 
prerequisite for these guidelines is that all polyps ≥ 5 mm in diameter has been removed, 
no suspicion of inherited genetic disorders with increased risk of CRC, no methodological 
flaws (e.g. inadequate examination, incomplete polypectomy, inadequate histopathology 
report) and that general health and life expectancy of the patient is reasonable.63  
1) Surveillance after 5 years 
a. Three or more adenomas removed 
b. Only biopsy of adenoma (i.e. inadequate removal) 
c. Adenoma(s) removed and personal history of gynecological cancer 
d. Adenoma(s) removed and having a first degree relative with CRC 
2) Surveillance after 10 years (if none of the criteria for 5-year surveillance have 
been met and there was: 
a. Adenomas with villous components 
b. Adenomas with high-grade dysplasia 
c. 1-2 adequately removed adenomas ≥ 10 mm in diameter 
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Primary study endpoints were CRC incidence and CRC mortality. Outcome data were 
obtained from the Cancer Registry and Cause of Death Registry. In addition, data on 
emigration was obtained from the Population Registry. 
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All included individuals in the control and screening arm in the NORCCAP trial were 
included in the serrated polyp study. We classified individuals in the screening arm into 
five groups according to screening compliance and findings at screening. For the purpose 
of this study, “screening” includes the flexible sigmoidoscopy screening and the 
colonoscopy of screen positive individuals. 
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1. Non-complier group: Individuals invited for screening who did not attend the 
screening examination. 
2. Non-advanced adenoma group: Individuals with 1-2 tubular adenomas < 10mm in 
diameter at screening and no villous components or high-grade dysplasia. 
3. Advanced adenoma group: Individuals with 3 or more adenomas or at least one 
adenoma with diameter ≥10mm, or with villous features or with high-grade 
dysplasia at screening.  
4. Serrated polyp group: Individuals with at least one serrated polyp with diameter 
≥10mm and no advanced adenoma at screening.  
5. Polyp free group: Individuals with neither adenomas nor serrated polyps ≥10mm 
at screening.  
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The screening intervention (flexible sigmoidoscopy screening and colonoscopy of screen-
positive individuals) has been described under “Paper I”. All histologic specimens from 
the screening intervention in the serrated polyp group were retrieved and re-evaluated 
according to modern classification of serrated polyps.54 Two experts in gastrointestinal 
pathology did the re-assessment separately. Results from the individual assessment were 
then compared, and in case of disagreement, the specimen was evaluated by the 
pathologists in companionship to reach consensus. In case of continued disagreement, a 
third expert pathologist assessed the final diagnosis.  
Hospital records of all patients in the serrated polyp group were searched for endoscopy 
reports and histopathology reports of polyps in the colorectum. All identified specimens 
were retrieved and reviewed in the same way as described above. 
All individuals in the serrated polyp group who were alive and had not been diagnosed 
with CRC by December 31st 2011 were invited for colonoscopy in September 2012. 
Telemark patients were examined at the hospitals in Kragerø or Skien, and patients living 
in Oslo were examined at Oslo University Hospital Rikshospitalet. If a polyp was found, 
polypectomy was performed, and subjected to histopathological evaluation as described 
above. 
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The primary study endpoint was CRC incidence. Information of all incident cancers 
during the study period was obtained from the Cancer Registry of Norway. Secondary 
endpoints were findings at colonoscopy performed after screening. 
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This randomized controlled trial was conducted at Sørlandet Hospital, Kristiansand, 
Norway, between August 10, 2007 and May 11, 2010. Eligible participants were patients 
older than 18 years referred for colonoscopy at the outpatient clinic and allocated to an 
endoscopy suite where both the MEI (ScopeGuide®; Olympus Optical Company Ltd, 
Tokyo, Japan) and C-bow fluoroscopy were available. Exclusion criteria were prior 
colonic resection, pregnancy, inability to understand written information, requirement of 
sedation before the start of the procedure, or implanted pacemaker or 
cardioverter/defibrillator. Patients allocated to the study endoscopy suite and who were 
eligible to participate were screened for exclusion criteria and, after provision of written 
informed consent, randomized by a dedicated study nurse to either standard colonoscopy 
with fluoroscopy on demand (standard group) or use of the MEI system (MEI group). 
Sealed envelopes to be drawn by the study nurse were used for randomization.  
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All procedures in both groups were performed using a standard colonoscope (Olympus 
CF-Q160DI provided with the Olympus ScopeGuide® system, outer diameter 13.2 mm), 
and ambient air was used for insufflation. In the standard group, C-bow fluoroscopy was 
available on demand. In the MEI group, colonoscopy was performed with the aid of the 
MEI system. Apart from the MEI/fluoroscopy system, all procedures were performed in 
the same way. An analgetic (pethidin) and/or sedation with midazolam were given only 
on demand.  
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The primary study endpoint was pain reported by the patient on a four-point Likert scale 
the day after the procedure. Pain-scores were dichotomized to no/slight/moderate pain or 
severe pain. Secondary endpoints were caecal intubation rate, procedure time, time to 
reach the caecum, the need for sedation/analgesia and need for assistance from a senior 
colleague to complete the procedure. Endpoints were obtained by questionnaires filled in 
by the patients and from endoscopy report forms. The seven endoscopists in the trial were 
categorized as experienced (more than 200 colonoscopies performed) or inexperienced 
(less than 200 colonoscopies performed).
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Analyses were conducted with SPSS version 16.0 (SPSS, Chicago, Illinois, USA) or 
STATA version 12 or 13 (StataCorp, College Station, Texas, USA). All tests were two-
sided and p<0.05 was considered as statistically significant. Categorical variables were 
compared using chi-square statistics or Fisher’s exact test. Continuous variables were 
tested for normality and were compared using Student’s t-test or Mann-Whitney-U test as 
appropriate. Logistic regression models were fitted to obtain odds ratios, and goodness of 
fit was tested with the Hosmer-Lemeshow test.83 Interobserver agreement was calculated 
with kappa statistics. 
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The survival analyses used in papers I and II merits more explanation: The 50-54 year 
and 55-64 year age-groups were merged for analyses (paper I and II). For CRC incidence, 
the number of person-years were calculated from the study entry-date until a diagnosis of 
CRC, death, emigration or December 31st 2011. For CRC mortality, the number of 
person-years were calculated from the study entry-date until death, emigration or 
December 31st 2011.  
We calculated age-standardized rates for CRC incidence and CRC mortality, and for all-
cause mortality. Because of the uneven ratio between screening- and control individuals 
in the 55-64 year compared with the 50-54 year age groups (1:3 versus 1:5.4, 
respectively), individuals in the control arm were on average younger than in the 
screening arm (56.1 and 56.9 years, respectively). As a result, a valid analysis of the trial 
data could not ignore the variable age group. To explain this approach, consider 
separately both age groups. Because of the randomized design, treatment effects are 
unconfounded within both the 50-54 and the 55-64 age groups. However, pooling both 
age groups into a single, unadjusted analysis may introduce confounding by age group. 
Table 2 displays the rate ratios (RR) for CRC incidence for the two age groups separately 
and combined. The RR of colorectal cancer incidence is 0.68 in the 50-54 year age group 
and 0.83 in the 55-64 year age group. However, for the two age groups combined, the 
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(unadjusted) RR is 0.88, which is higher than the age-specific analyses and obviously 
incorrect. We therefore standardized the incidence rates according to the screening group.  
Table 2: Age-specific and overall rate ratios for colorectal cancer incidence in the 
screening arm compared to the control arm. Both non-standardized and age-standardized 
rate ratios, are given. RR: Rate ratio, CI: Confidence Interval, CRC: Colorectal cancer 
 
We used Cox proportional hazard models to estimate relative risks (hazard ratio, HR) 
of the endpoints in the screening arm compared to the control arm (paper I). We 
included age-group (50-54 vs 55-64 years) as a binary covariate because of the age-
difference between the screening and control arm (the age-difference was due to 
different screening-control ratio in the two age-groups: if we included age as a 
continuous variable, the results were identical). In paper II, sex was also included as a 
covariate. The Cox model assumes that the ratio of the hazards in the groups that are 
compared is constant. For the disease-specific and all-cause mortality analyses, the 
proportionality assumption was met, analyzing smoothed plots of Schoenfeld’s 
residuals.84 The proportionality assumption was not met when the cumulative 
incidence curves cross as they do in our CRC incidence analyses (papers I and II), and 
use of the Cox-model may seem inappropriate. However, it has been argued that the 
hazard ratio may be interpreted as the average causal effect across the entire study 
period and population, an interpretation that is clinically meaningful.85,86 It is 
important to be aware that in case of non-proportionality, HRs may be sensitive to time 
which means that different HRs may be obtained conditional on when the cut-off for 
end of follow-up is set (table 3). 
 
  
 
Screening 
 
 
Control 
 
 
Screening 
 
 
Control 
RR  
(Non-
standardized)  
(95% CI) 
RR  
(Age-
Standardized) 
(95% CI) 
 Cases (n) Person-time (years)   
CRC incidence       
   50-54 years 40 315 69960 373671 0.68 (0.48-0.94)  
   55-64 years 213 771 151469 454536 0.83 (0.71-0.97)  
   50-64 years 253 1086 221429 828207 0.88 (0.77-1.01) 0.80 (0.70-0.92) 
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Table 3: Colorectal cancer incidence in the screening arm compared to the control 
arm (intention-to treat). The table shows hazard ratios adjusted for age with 95% 
confidence intervals (CI) for different time intervals from screening to end of follow-
up.  
 
Time from screening to follow-up 3 years 6 years 9 years 12 years 
 
Hazard ratio 
(95% CI) 
 
1.21 
(0.93-1.58) 
 
1.01 
(0.83-1.24) 
 
0.91 
(0.78-1.07) 
 
0.80 
(0.69-0.92) 
 
To test whether the Cox-model provided erroneous estimates in paper I, we compared 
the age-standardized incidence rate ratios and the hazard ratios derived from the Cox 
model (Table 4), using the standardized incidence rates from table 2 in paper I. As 
shown in table 4, the results were identical, implying that the Cox model provides 
valid estimates. 
 
 
Table 4: Comparison of hazard ratios obtained from the Cox-model and age-
standardized incidence rate ratios in paper I. CI: Confidence interval 
 Hazard ratio with 95% CI 
(Cox) 
Incidence rate ratio with 95% CI 
(Age-standardized) 
 
Colorectal cancer incidence 
 
0.80 (0.70-0.92) 
 
0.80 (0.70-0.92) 
Colorectal cancer mortality 0.73 (0.56-0.94) 0.73 (0.56-0.94) 
All-cause mortality 0.97 (0.93-1.02) 0.97 (0.93-1.02) 
 
  32 
For estimation of the effect of screening adjusted for non-compliance, we used 
instrumental variable estimation with the randomization indicator (randomized to 
screening or to no screening) as the instrument (see section 7.2).87  
Number needed to treat (actually: to invite) to prevent one CRC diagnosis or CRC death 
after 10 years were calculated as the inverse of the absolute risk difference between the 
screening group and the control group. 
We calculated the incremental cost-effectiveness ratio (ICER) by means of prevented 
CRC diagnosis and CRC death in a 10-year perspective. Only direct costs were 
considered. Total costs were calculated as the combined cost of screening and treatment 
for CRC in the screening arm minus the cost of CRC treatment in the control arm. The 
number of prevented CRC cases and CRC deaths were calculated as the expected number 
of CRC cases and CRC deaths minus the observed numbers. Expected numbers were 
calculated by multiplying the incidence and mortality rate in the control arm with the 
corresponding number of person-years in the screening arm. The ICER was then obtained 
by dividing the total costs with the number of prevented CRC cases and CRC deaths (See 
supplementary appendix in paper I).  
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All screening attenders in paper I provided written informed consent. The NORCCAP 
trial was approved by the Regional Ethics Committee and the Norwegian Data Protection 
Authority. The trial is registered in a clinical trial database (http://www.clinicaltrials.gov, 
identifier NCT00119912).  
The study in paper II was conducted within the framework of the NORCCAP trial. The 
re-invitation for colonoscopy was waived approval from the Regional Ethics Committee. 
All participants in paper III provided written informed consent. The trial was approved by 
the Regional Ethics Committee and the Norwegian Social Science Services. The trial is 
registered in a clinical trial database (http://www.clincaltrials.gov, identifier 
NCT00519129).  
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Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and 
mortality. A randomized clinical trial 
JAMA 2014;312:606-615 
After median 10.9 years of follow-up (11.2 years in the intervention arm and 10.9 years in 
the control arm), 253 individuals had been diagnosed with CRC in the screening arm, and 
1,086 in the control arm. CRC incidence was thus reduced by 20% in the screening arm 
compared to the control arm, HR 0.80 (95% CI 0.70-0.92). Seventy-one individuals had 
died from CRC in the screening arm, and 330 in the control arm, corresponding to a 27% 
reduction in CRC mortality, HR 0.73 (95% CI 0.56-0.94). CRC incidence was reduced in 
both the 50-54 year age-group (HR 0.68; 95% CI 0.49-0.94) and in the 55-64 year age 
group (HR 0.83; 95% CI 0.71-0.96). The effect on CRC incidence and mortality was 
comparable in the flexible sigmoidoscopy and the flexible sigmoidoscopy + FOBT 
screening group. 
In the per protocol analyses (after 10 years of follow-up, adjusting for non-compliance), 
the absolute risk reduction in CRC incidence was -0.42% (95% CI -0.69% to -0.15%) as 
compared to -0.22% (95% CI -0.38% to -0.06%) in the intention-to treat analysis. For 
CRC mortality, the risk reduction was -0.10% (95% CI -0.25% to 0.05%) in the per 
protocol analysis and -0.06% (95% CI -0.14% to 0.03%) by intention-to-treat. 
We estimated the number needed to treat and the incremental cost-effectiveness ratio after 
10 years of follow- up. To prevent one CRC case, 455 individuals had to be invited for 
screening at a cost of $58.448 per CRC case prevented. To save one death from CRC, 
1667 individuals had to be invited for screening at a cost of $226,002 per CRC death 
prevented. 
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Long-term risk of colorectal cancer in individuals with serrated polyps 
 
GUT, epub ahead of print 
http://gut.bmj.com/content/early/2014/11/10/gutjnl-2014-307793.short?rss=1 
 
This study was conducted within the framework of the NORCCAP trial (paper I). We 
categorized individuals in the screening arm into five groups according to screening 
compliance and finding at the screening examination (including follow-up colonoscopy of 
screen-positives) as described previously: 
Compared to the individuals without adenomas or polyps ≥10 mm (polyp free group) 
detected at screening, individuals with large serrated polyps (serrated polyp group) had 
increased risk for a CRC diagnosis after median 10.9 years of follow-up, HR 4.2 (95% CI 
1.3-13.3) The risk was comparable to individuals with advanced adenomas who had a HR 
for CRC incidence of 3.3 (95% CI 2.1-5.2) compared to the polyp-free group (P=0.7 for 
comparison). The risk for CRC in individuals in the serrated polyp group was larger than 
for individuals with non-advanced adenomas who had a HR of 1.1 (95% CI 0.6-1.9) 
compared to the polyp-free group (p=0.03 for comparison). Compared to the general 
population, the risk for CRC in the serrated polyp group was 2.5 times higher, but this 
result did not reach statistical significant difference, HR 2.5 (95% CI 0.8-7.7). The HR for 
CRC incidence for individuals with advanced and non-advanced adenoma compared to 
the general population was 2.0 (95% CI 1.3-2.9) and 0.6 (95% CI 0.4-1.1), respectively. 
Having a serrated polyp ≥10 mm was an independent risk factor for being diagnosed with 
CRC in a multivariate logistic regression model adjusting for age, sex and characteristics 
of concomitant adenomas (Odds ratio 3.3, 95% CI 1.3-8.6). 
Twenty-three serrated polyps ≥10mm left in situ (only biopsied in the screening trial) for 
median 11 years. In none of these individuals, CRC developed in the same colon segment 
as the index polyp left in situ, and few polyps increased in size.  
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Magnetic endoscopic imaging versus standard colonoscopy in a routine colonoscopy 
setting: a randomized, controlled trial 
Gastrointestinal Endoscopy 2011;73:1215-1222 
A total of 810 individuals scheduled for outpatient colonoscopy at Sørlandet Hospital 
Kristiansand between 2007 and 2010, and who were willing to start the procedure without 
sedation or analgesia, were randomized to examination with MEI-aided colonoscopy 
(n=419) or standard colonoscopy (n=391) with fluoroscopy on-demand. We found no 
significant difference in the proportion of patients with severe pain between the MEI-
guided (12.6%) and the fluoroscopy on demand colonoscopy group (16.7%), p=0.15. The 
results were the same for experienced and inexperienced endoscopists.  
For experienced endoscopists, we did not detect any difference in the two study arms for 
caecum intubation rate, time to reach the caecum, need for assistance or use of 
sedation/analgesia. Inexperienced endoscopists, on the other hand, had a higher caecum 
intubation rate (77.8% vs 56.0%, p=0.02) and less need for assistance (18.5% vs 40.0%, 
p=0.02) with MEI-guided colonoscopy than with standard colonoscopy. There was no 
difference in use of sedation/analgesia or time to reach the caecum in the two study arms 
for inexperienced endoscopists. 
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CRC is an important health problem. In Norway, about 3800 persons were diagnosed 
with CRC in 2011,2 and the disease accounted for 3.8% of all deaths in 2012.3 As it is 
believed that CRC arises from benign precursors, the disease may be preventable. 
Screening for CRC has thus been implemented in many countries.6,7 
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We found that CRC incidence was reduced by 20% and CRC mortality by 27% (paper 
I).35 In the previously published flexible sigmoidoscopy screening trials, CRC incidence 
in these trials was reduced by 18-23% and CRC mortality by 22-31%.32-34 The results are 
thus remarkable consistent despite the disparity in design (post- versus pre-consent 
randomization), the age of the individuals included in the different trials and the possible 
contamination of the individuals in the control arm by screening outside the trial. A meta-
analysis of the four trials (using fixed-effect Mantel-Haenszel model) shows that the 
pooled risk ratio for CRC incidence is 0.78 (95% CI 0.75-0.83), in the screening arm 
compared to the control arm (figure 6).  
Figure 6: Meta-analysis of CRC incidence in the four flexible sigmoidoscopy screening 
trials. NORCCAP: Norwegian Colorectal Cancer Prevention trial, PLCO: Prostate, 
Lung, Colorectal and Ovarian cancer screening trial (USA), SCORE: Screening Colon 
Rectum (Italy). The Flexi Scope trial was conducted in the United Kingdom. 
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For CRC mortality, the pooled risk ratio is 0.72 (95% CI 0.66-0.80) in the screening arm 
compared to the control arm (figure 7). Most importantly, there is no statistical 
heterogeneity between the trials for neither CRC incidence nor mortality (figure 6 and 7: 
I2=0%). 
Figure 7: Meta-analysis of CRC mortality in the four flexible sigmoidoscopy screening 
trials. 
It is interesting to compare the four randomized controlled trials of flexible 
sigmoidoscopy in terms of effect on CRC incidence in the distal versus proximal colon. It 
has been shown in previous trials that individuals with a distal adenoma have increased 
risk of proximal advanced neoplasia (defined as advanced adenoma and CRC), even if the 
results from these trials diverge with respect to the importance of different adenoma 
characteristics.30,31,88 One might expect that the trials with the highest colonoscopy 
referral rate after screening reduced proximal CRC incidence the most, but there is 
evidence in the literature that colonoscopy may not reduce incidence of advanced 
proximal neoplasia or CRC 89,90 or death due to proximal CRC.91,92  
The four flexible sigmoidoscopy trials had important differences in the threshold for 
referral to colonoscopy. In the NORCCAP trial, CRC, any adenoma (irrespective of size) 
or any polyp 10 mm or larger (or positive FOBT) qualified for colonoscopy. In the PLCO 
(Prostate, Lung, Colorectal and Ovarian cancer screening) trial from the US,33 all 
individuals with any detected polyp or mass were referred for colonoscopy. In the UK 
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Flexi Scope trial, people with any polyp ≥ 10 mm, adenomas with high-grade dysplasia or 
villous/tubulovillous histology, multiple adenomas (three or more) or ≥ 20 hyperplastic 
polyps above the distal rectum or CRC were offered colonoscopy.32 In the Italian SCORE 
(Screening Colon Rectum) trial, individuals with a polyp > 5 mm, adenoma with high-
grade dysplasia or villous/tubulovillous histology, multiple adenomas (three or more) or 
CRC were referred for colonoscopy.34 These differences led to widely varying 
colonoscopy rates (19.5% in NORCCAP; 5.0% in Flexi Scope; 7.8% in SCORE and 
21.9% in the PLCO trial). Of note, individuals in the PLCO trial were offered two 
screening examinations 3-5 years apart, while only one examination was offered in the 
other three trials. The reduction in CRC incidence of the distal colon and rectum was 
comparable between the trials (24-36% with overlapping confidence intervals). The 
reduction in proximal CRC incidence, however, was more varying between the trials and 
increased as the colonoscopy rate increased, from 2% reduction in the Flexi Scope trial to 
14% in the PLCO trial (a 7-fold difference, a statistically significant reduction in the 
PLCO trial only). This is consistent with recent observational studies that suggest a 
protective effect of colonoscopy also on proximal CRC incidence93 and CRC mortality.94 
Figure 8: Comparison of the four flexible sigmoidoscopy screening trials: Proportion of 
screening compliers who had a colonoscopy and relative reduction in CRC incidence in 
the distal and proximal colon in the screening arm compared to the control arm. 
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However, even referring all individuals with a pathologic finding at flexible 
sigmoidoscopy screening to colonoscopy is not very efficient in reducing proximal CRC 
incidence and mortality.33 About 70% of advanced adenomas in the entire colon and 
rectum are detected if individuals with any adenoma at screening flexible sigmoidoscopy 
are referred for colonoscopy.95 About 50% of individuals with proximal advanced 
neoplasia do not have a distal adenoma which could trigger a full colonoscopy, and in a 
recent study, it was shown that 52% of proximal advanced serrated polyps (TSA, SSA/P 
with dysplasia, SSA/P with size ≥10mm in diameter) do not have a distal polyp.30,37  
In the Spanish COLONPREV-trial, a randomized trial comparing colonoscopy to biennial 
faecal immunochemical testing (FIT), the baseline findings from the colonoscopy 
screening arm or colonoscopy crossover from the FIT-arm (total n=5059) were used to 
simulate different yield of proximal or any advanced neoplasia according to the different 
colonoscopy referral criteria in NORCCAP, SCORE and Flexi scope.40,96 The detection 
rate of any advanced neoplasia at colonoscopy in COLONPREV was 10.3%. If the Flexi 
Scope, SCORE or NORCCAP criteria for colonoscopy were applied, the detection rates 
were only modestly different; 6.3%, 6.7% and 7.0%, respectively, although the 
differences reached statistical significance.96 Colonoscopy referral rates, when the 
different criteria were applied to the COLONPREV-participants, were 6.2%, 12.0% and 
17.9%. Accordingly, a three-fold increase in colonoscopy-referral rate (from 6.2% to 
17.9%) increased the sensitivity for detection of any advanced neoplasia only from 61% 
(317/520) to 68% (355/520). The sensitivity for detection of any proximal advanced 
neoplasia was 22%, 31% and 37%, respectively. Of note, only 1 of 6 proximal CRC in the 
COLONPREV trial would have been detected by screening sigmoidoscopy, regardless of 
referral strategy. 
 Interestingly, having isolated proximal advanced neoplasia/adenoma has been suggested 
to be more common amongst women than men.97,98 This may be the reason why we in the 
NORCCAP trial found a smaller, though not statistically significant, effect on CRC 
mortality and incidence in women than in men. Also the PLCO trial reported a lower 
effectiveness of flexible sigmoidoscopy screening in women than in men, but the 
difference did not reach statistical significance.33 On the other hand, in the SCORE trial, 
women had a larger reduction in CRC incidence than men (not statistically significant), 
but is also the smallest of the four trials.34 In the abovementioned COLONPREV 
simulation study, the sensitivity for detection of advanced proximal neoplasia was 
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significantly lower in women than men, regardless of colonscopy referral criteria.96 Taken 
together, these results suggest that there may be a difference in effectiveness of flexible 
sigmoidoscopy screening between men and women and should be explored further. It 
would be very interesting to perform a meta-analysis stratified by sex of the four trials. 
The age at when to start screening has not been firmly established. US guidelines 
recommend starting at 50 years,7 but evidence for this recommendation from randomized 
controlled trials is limited. The NORCCAP trial included individuals from 50 years of 
age, while the other three trials included individuals 55 years and older. Our results show 
that flexible sigmoidoscopy screening reduces CRC incidence also in the 50-54 year age 
group (HR 0.68, 95% CI 0.49-0.94). This indicates that screening for CRC should start at 
age 50, but it should be remembered that the age-specific results are subgroup analyses, 
and the results should thus be interpreted with caution.  
Complications to screening should also be mentioned. Among 12 955 individuals 
screened with flexible sigmoidoscopy in NORCCAP, there were no complications, but 
detected polyps were biopsied only. There were 6 perforations  (1 in 336 therapeutic 
colonoscopies: 0.3%) , all due to polypectomies during colonoscopy.25 The complication 
rate was higher than in the three other flexible sigmoidoscopy trials. The reason for this is 
unknown; all the endoscopists in the NORCCAP trial were experienced. In a report from 
the English bowel screening program, there were 63 perforations  in 69 028 therapeutic 
colonoscopies (0.09%, one third compared to the perforation rate in NORCCAP).99 All 
the endoscopists in the English screening programme have to be accredited and undertake 
a written and practical examination, and quality indicators are measured continuously.100 
Educating endoscopists and continuous quality assurance surveillance is important to 
minimize harm in association with CRC screening. 
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The standard approach for analyzing data from a randomized controlled trial like 
NORCCAP is the intention-to-treat approach, meaning that every individual in the 
screening arm is included in the analysis, no matter whether they received the 
intervention or not. An intention-to-treat calculation will give a conservative effect 
estimate (biased towards the null) of the intervention when compliance is not 100%. An 
  42 
intention-to-treat analysis will estimate the effect of being assigned to the intervention 
(e.g. invitation for screening), rather than the intervention itself. What we really want to 
know is the true effect of the intervention itself. Thus, we aimed at estimating the “per 
protocol-effect”, that is, the effect of the screening intervention if everyone was compliant 
with the trial protocol (everyone assigned to screening attended their screening 
examination and no one in the control arm had a screening examination), see appendix of 
paper I. 
Our first approach was to collect as much information about the participants (in both the 
control and screening arm) as possible to uncover factors that predicted compliance with 
screening. Using this information, we intended to perform propensity score 
matching/adjustment.101 To perform such an analysis, however, we had to identify all 
joint predictors of compliance and the outcome (e.g. CRC incidence and mortality). 
Usually, this assumption is not empirically verifiable, but in the NORCCAP trial, we 
could test whether compliance occurred at random. If it occurred at random, then the 
CRC incidence rate and mortality rate would be the same in the control arm as in the non-
compliers. For CRC incidence, this was indeed true. The age-adjusted HR for CRC 
incidence in the non-compliers as compared to the controls was 1.02 (95% CI 0.84-1.24). 
This means that the CRC incidence risk was similar in the non-compliers and the 
controls, and that the CRC incidence reduction amongst the compliers was only due to the 
intervention, not to selection. This gave us the opportunity to estimate the effect of the 
screening intervention (per-protocol effect) by fitting a Cox model comparing the 
compliers to the control arm. The age-adjusted HR for the per protocol effect for CRC 
incidence was 0.68 (95% CI 0.57-0.81) as compared to 0.80 (95% CI 0.70-0.92) in the 
intention-to-treat analysis..  
For CRC mortality however, the HR was 1.35 (95% CI 0.99-1.85) in the non-compliers 
compared to controls, and was only marginally changed when we included all obtainable 
socioeconomic and comorbidity variables (Table 1 in the appendix of paper I). This 
means that controls and non-compliers are at different risk with respect to CRC mortality 
(35% higher among noncompliers compared to controls), and that adjustment for 
variables that may predict compliance is insufficient to eliminate this difference. 
The results from the CRC mortality analysis indicate that all analyses which require 
adjustment for joint predictors of compliance and CRC mortality will be biased. This also 
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includes propensity score matching which was our initial intention. We thus used 
instrumental variable (IV) estimation to adjust for non-compliance, with the 
randomization indicator (randomized to screening or to no screening) as the instrument, 
which does not require adjustment for the joint predictors.87 
When we consider the Directed Acyclic Graph (DAG) in figure 9, we can see that the 
randomization meets the three basic assumptions for an instrument: 
1) Z is associated with X 
2) Z affects the outcome Y only through X, and 
3) There is no confounding of Z on Y 
 
U 
 
Z  X    Y 
 
Figure 9: Directed Acyclic Graph. Z: Randomization indicator; X: Screening intervention 
(flexible sigmoidoscopy); Y: Outcome (Colorectal cancer incidence or mortality); U: 
Unmeasured and measured confounders.  
 
In other words: The randomization indicator is likely to meet the three instrumental 
assumptions: randomization is strongly associated with attendance to screening, we 
expect no effect of randomization on the outcome except through screening (called the 
exclusion restriction), and we expect the intention to treat effect to unbiasedly estimate 
the effect of assignment (no confounding for the effect of the instrument).  
 
The intention to treat risk difference between the screening arm and the control arm can 
be written as:  
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 P(Y|Z=1) – P(Y|Z=0) 
Where P is the probability of the outcome Y and Z is the randomization indicator. Z=1 
indicates randomization to screening, and Z=0 indicates randomization to no screening 
(control arm). 
Using Z as an instrument, we can write the per protocol effect (adjusted for non-
compliance) as:87 
 P(Y|Z=1) – P(Y|Z=0) 
 P(X|Z=1) – P(X|Z=0) 
 
where P(X|Z=1) indicates the probability of receiving the intervention conditioning on 
randomization to the screening arm (that is, compliance), and P(X|Z=0) indicates the 
probability of receiving the intervention conditioning on randomization to the control arm 
(that is, contamination). From the Norwegian Gastronet data, we know that screening for 
colorectal cancer is a rare indication for colonoscopy in Norway,47 and there has been no 
organized screening for CRC in the trial period, which means that P(X|Z=0) is zero for all 
practical purposes. Therefore, the per protocol risk difference equals: 
 P(Y|Z=1) – P(Y|Z=0) 
           P(X|Z=1) 
 
As this instrumental variable calculation is on the risk difference scale, we restricted our 
calculation to 10 years of follow-up. We had to apply this approach because all 
individuals in NORCCAP had at least 10 years follow-up. To calculate the risk, every 
individual in the denominator must have the possibility to be a case (e.g. diagnosed with 
CRC or die from CRC), that is, included in the numerator.  
We calculated the intention-to-treat risk difference to be -0.22% (95% CI -0.38 to -0.06) 
and the IV multivariate adjusted risk difference to -0.42% (95% CI -0.69 to -0.15). For 
CRC mortality, the intention-to-treat risk difference was -0.06% (95% CI -0.14 to 0.03) 
and the IV multivariate adjusted risk difference was -0.10% (95% CI -0.25 to 0.10). This 
means that the estimated per protocol effect is considerable higher than the intention-to-
treat estimate.  
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The interpretation of the per-protocol effect using instrumental variable estimation has an 
important limitation. In addition to the three above mentioned assumptions, our 
calculations were based on the assumption of monotonicity. Monotonicity indicates that 
we assume that there are no defiers, that is, that there are no individuals in neither the 
control arm nor the screening arm who will do exactly the opposite of what they were 
randomized to. This assumption implies that the per-protocol calculation estimates the 
effect of the intervention in those who would have complied with the screening invitation, 
and not the effect in the entire study population. 
It is of interest that also the SCORE and Flexi Scope trial estimated a per-protocol 
effect,32,34 but they used another method (described by Cuzick et al).102 The reported 
increase in efficacy of flexible sigmoidoscopy screening in these per protocol analyses 
was of the same magnitude as in the univariate (age-adjusted) IV analyses of the 
NORCCAP data (see eTable 2 in the appendix). The method described by Cuzick is also 
an instrumental variable estimation with the same important limitation as outlined 
above.103 For example, the per protocol (compliance-adjusted) decline in CRC mortality 
in the Flexi Scope trial was 43% (HR 0.57, 95% CI 0.45-0.72). This may be interpreted as 
the effect of flexible sigmoidoscopy screening on CRC mortality in the entire study 
population. But due to the assumptions mentioned above, it should be interpreted as the 
effect of flexible sigmoidoscopy screening among the compliers only.  
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Screening with flexible sigmoidoscopy may reduce CRC mortality by prevention and by 
early detection, but it is uncertain which of the two mechanisms that contributes the most. 
In NORCCAP, more CRCs were observed in the screening arm than the control arm the 
first year after inclusion in the trial due to screen-detected cancers. But after this first 
year, fewer CRCs are observed in the screening arm than in the control arm (risk ratio 
below 1 in figure 10). Even if the number of incident cases (CRC diagnosis) are few each 
year, and the confidence intervals cross 1 most of the years, these results indicate that the 
effect of a once only flexible sigmoidoscopy screening on CRC incidence is long lasting 
and may affect CRC mortality beyond the follow-up time of the trial. 
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Figure 10: Yearly risk ratio for CRC incidence in the screening arm compared to the 
control arm. 
 
Similarly, figure 11 shows the yearly risk ratio for CRC mortality in the screening arm 
relative to the control arm. There is a small initial reduction in CRC mortality 
(statistically non-significant due to few number of CRC-related deaths) already the first 
years after screening. This reduction is probably due to detection of less advanced cancers 
with a favorable prognosis at screening: 71% of screen-detected CRCs were Dukes A or 
B, compared to 43% in controls (Table 4 in paper I). In the first few years after screening, 
CRC incidence reduction is probably less important for CRC mortality as it takes some 
time from development from adenoma to symptomatic cancer to death. But as time from 
screening increases, there are fewer CRCs detected in the screening arm than in the 
control arm (figure 10 and figure 2 in paper I). From figure 11, the larger effect on CRC 
mortality evolves 9 years after screening. This probably reflects the effect of 
polypectomy, and the resulting decline in CRC incidence.  
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Figure 11: Yearly risk ratio for CRC mortality in the screening arm relative to the control 
arm. 
 
Thus, the reduction in CRC mortality is caused by both early detection and 
prevention. It is difficult to conclude which mechanism is most important. Only 41 
of 253 (17%) CRCs in the screening arm were screen-detected, but we have no 
information of adherence to the surveillance recommendation. Surveillance 
colonoscopies may have contributed to both a more favorable stage at diagnosis 
compared to CRCs in the control arm, but also to prevention by additional 
polypectomies. 
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At the time the flexible sigmoidoscoscopy trials were conducted (1993-2001), non-
adenomatous polyps were considered to have no malignant potential as stated in the 3rd 
edition of WHO classification of tumors in the digestive system, published in 2000.104  
Later research has, however, suggested an association of large serrated polyps with 
synchronous advanced neoplasia and CRC.105,106 Very recently, a large nested case-
control study from Denmark showed that the risk of metachronous CRC in individuals 
with SSA/P was of similar magnitude as individuals with adenomas and higher when 
compared to individuals without polyps.107 
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In NORCCAP, we found that 0.8% of screenees had a large serrated polyp (≥ 10mm in 
diameter). This is lower than other estimates which range from 1.4-2.6%.105,106,108 This 
probably reflects the fact that individuals with large serrated polyps in our series were 
identified during flexible sigmoidoscopy, and not through colonoscopy. But the low 
detection rates may also be attributed to the assumption of no malignant potential for 
these polyps, and some polyps with appearance as hyperplastic polyps may not have been 
biopsied. Low detection rates may also be due to missed lesions as there is a high inter-
endoscopist variation in detection of serrated polyps.109 Variable detection rates between 
endoscopists for any polyp and for adenomas has been reported in the NORCCAP trial.110 
Unlike other trials, we did not report an increased risk of synchronous CRC in patients 
with serrated polyps.106 This is due to how individuals were classified. In our trial, 
individuals with large serrated polyps with concurrent advanced adenomas were classified 
in the advanced adenoma group. If we had included these 22 individuals in the serrated 
polyps group, 1 CRC had been screen-detected among 103 (1%) individuals with a large 
serrated polyp as compared to 40 CRC in all 12,852 screening attenders without a large 
serrated polyp (0.3%).  
We found that the presence of a large serrated polyp was associated with CRC during 
almost 11 years of follow-up. The risk was about 4-fold compared to the risk in 
individuals without polyps detected at screening, HR 4.2 (95% CI 1.3-13.3). Compared to 
the general population, represented by the NORCCAP control arm, the HR was 2.5 (95% 
CI 0.8-7.7), and did not reach statistical significance. The proportion of individuals with 
CRC in the serrated polyp group was 3.7%. Previous retrospective studies have also 
suggested an association between serrated polyps and metachronuos CRC: Lu and 
colleagues reported on 40 individuals with non-dysplastic SSA/P. After 8-28 years, five 
(12.5%) developed CRC compared to 1.8% of patients with hyperplastic polyps or 
conventional adenomas.111 Teriaky reported on a 5-year follow-up of 33 individuals with 
SSA/P or mixed SSA, and one patient (5%) developed CRC.112 Lazarus found that 2 of 
38 (5%) of individuals with dysplastic SSA/P developed CRC, but follow-up time in this 
study was not reported.113 Our estimate of absolute CRC risk is lower, but direct 
comparison is difficult due to different time to follow-up and inclusion criteria. 
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We found that the risk of CRC in the serrated polyp group was comparable to  individuals 
with advanced adenomas, HR 1.3 (95% CI 0.4-4.2) and higher compared to individuals 
with nonadvanced adenomas, HR 3.9 (95% CI 1.1-13.2).  
 
We also compared the risk of metachronous CRC in individuals with advanced adenomas 
and serrated polyps, that is, the risk after the screening examination (excluding screen-
detected CRCs from the analyses). We found that the risk of future CRC is at least as 
great in individuals with serrated polyps as in individuals with advanced adenomas; 
Hazard ratio 3.2 (95% CI 0.9-11.4). As in our primary analysis, also this analysis should 
be interpreted with caution as the number of CRC cases are low (indicated by the width of 
the confidence intervals). Another potential bias regarding this conclusion is the 
differences in surveillance recommendations. Eighty-five per cent of individuals in the 
advanced adenoma group were recommended surveillance compared to 53% of 
individuals with a large serrated polyp (unpublished data).  However, surveillance 
recommendation was not an independent risk factor for metachronous CRC when this 
variable was included in the Cox model (p=0.8, unpublished data), and did not change the 
effect estimates. 
It is unclear whether the increased CRC risk in individuals with large serrated polyps is 
confined to those whose large serrated polyp is a hyperplastic polyp or diagnosed as 
SSA/P.60 We were not able to disentangle this potential difference in association for 
several reasons. First, we did not have enough statistical power (e.g. few CRC cases). 
Second, about one fifth of the serrated polyps could not be classified as either 
hyperplastic polyp or SSA/P. Third, multiplicity was a frequent finding in our cohort, a 
feature which has been associated with the serrated pathway.114 Sixty-one per cent of 
individuals in our cohort had both hyperplastic polyps and SSA/P, and assessing CRC 
risk just based on which subgroup of serrated polyps had the largest size was not 
meaningful in our cohort. 
The natural history of serrated polyps has previously been partly described by Lazarus, 
but he did not separate hyperplastic polyps from SSA/P.113 We found that among 21 
patients, harboring 23 large serrated polyps left in situ following biopsy, none of the 
polyps progressed to CRC, and there was modest growth during 11 years of follow-up. In 
a previous study of non-resected polyps > 10 mm from the Mayo clinic, the CRC risk at 
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the polyp site was about 1% per year (1 per 100 person-years of observation).115 
Compared to our cohort of 23 serrated polyps followed for median 11 years (about 250 
personyears of observation), we should have observed at least 2 CRC cases at the site of 
the polyp left in situ if the risk were the same as in the cohort from the Mayo clinic, but 
we detected none. Again, our numbers are small, but indicate that the large serrated polyp 
may be a marker of increased risk of CRC elsewhere in the colon of these patients (so-
called field effect), and not be the premalignant lesion itself. Another study conducted by 
Bouwens and colleagues reported results that were different from ours (results reported as 
letter only).116 In this study, 3 out of 18 patients (17%) with proximal hyperplastic polyps 
larger than 5mm that were only biopsied developed CIMP-high BRAF-mutated CRC 
after 3, 5 and 9 years in the same colonic segment as the polyp left in situ. The reason for 
the discrepancy between this and our study may be that most of our large serrated polyps 
were located in the distal colon (14 of 23). Large proximal serrated polyps may have a 
different clinical course than large distal serrated polyps. Another reason may be that the 
polyps in our study were detected in a screening population, while patients in the Bouwen 
study were probably identified through diagnostic colonoscopies, even if this is not 
clearly stated in the report. 
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We found that 63% of individuals with a large serrated polyp had a concurrent adenoma, 
and 21% had an advanced adenoma. Theses numbers are considerably higher than the 
30% and 5.7%, respectively, found in a recent systematic review of asymptomatic 
individuals.117 Further, 56% of individuals in the serrated polyp group had 3 or more 
serrated polyps at screening. These results indicate that serrated polyps are associated 
with multiplicity of both adenomas and serrated polyps, a finding also suggested by other 
authors.114,118  
High level of methylation of Cytosine-rich promoter regions (CIMP-high) is associated 
with increasing size of serrated polyps,59 but also with size and villousness of 
adenomas.58,119 Thus, individuals with large serrated polyps may be prone to develop 
other serrated and adenomatous polyps, suggesting a “serrated environment” or a “field 
effect” in the colorectum which may be a driving force in both the adenoma-carcinoma 
sequence and the serrated pathway. Indeed, individuals with both serrated polyps and 
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adenomas may have larger serrated polyps, and larger and more advanced adenomas 
compared to individuals with only one type of polyp.118 One study also described that 
adenomas in individuals with serrated polyps had more atypical histologic features than 
adenomas in individuals without concurrent serrated polyps.120 Very recently, a study 
showed that 20% of CIMP-high CRCs had adenomatous polyps contiguous with the 
tumor, suggesting that CIMP-high tumors may evolve also from adenomas.121 
 In existing US and European postpolypectomy surveillance guidelines, serrated polyps 
and adenomas are treated separately.61,62 It may be that both kinds of polyps should be 
considered together (the “Total polyp load”) when CRC risk, and hence surveillance 
interval, is assessed. 
Our results indicate that large serrated polyps themselves may have an indolent course. 
There is uncertainty in the literature how rapid the growth of serrated polyps is, and 
consequently, there is uncertainty to how frequent surveillance colonoscopy should be 
recommended. Case reports have suggested that the transition from SSA/P to CRC may 
be rapid.122-125 However, a large series of 2,139 individuals with SSA/P showed that the 
mean age in persons with SSA/P without dysplasia was 61 years, 72 years in those with 
SSA/P harboring high-grade dysplasia, and 76 years in individuals with SSA/P harboring 
CRC, suggesting that transition from SSA/P to CRC may take 15 years.126 In another 
study by Lu et al of 55 individuals with SSA/P, the mean time from detection of SSA/P to 
advanced adenoma or CRC was 8.3 years.111 We found that the median time from 
detection of a large serrated polyp to CRC was 7.5 years, suggesting that surveillance 
intervals after detection of large serrated polyps may be extended beyond three years as is 
the current recommendations in US and European postpolypectomy surveillance 
guidelines.61,62 Interestingly, only 1 of 6 advanced adenomas (n=1) or CRC (n=5) at 
follow-up was located in the same colon segment as the index SSA/P in the Lu study. 
This is consistent with our findings: Only 1 of the 3 CRCs in the serrated polyps group 
were located in the same colon segment as a serrated polyp found at screening. These 
results indicate that it may not be the polyp per se that develops into a tumor, but 
strengthens the theory of the field-effect, although our numbers are very small. 
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Our study of serrated polyps has several limitations, of which low statistical power due to 
few CRC cases is the most obvious and probably led to a statistically non-significant 
result when we compared the serrated polyp group to the NORCCAP control arm. 
Another limitation is that the polyps in our study were identified during screening flexible 
sigmoidoscopy. The proximal colon was not investigated in about 80% of the screening 
attenders. A number of these individuals may have had proximal lesions (both adenomas 
and serrated polyps), not detected at flexible sigmoidoscopy, and thus were classified as 
polyp-free. The possible bias due to this would most probably result in an underestimate  
of CRC risk in individuals with large serrated polyps, although an opposite effect is 
theoretically possible, known as the Will-Rogers phenomenon:127 A third limitation is 
related to the initial classification of the large serrated polyps left in situ. This 
classification was based on biopsy specimens only. As the histologic differences between 
SSA/P and hyperplastic polyps may be subtle and unevenly distributed in the polyp, 
misclassification may have occurred. Thus, relation between initial diagnosis and follow-
up diagnosis must be interpreted with this in mind. Fourth, our observations may be 
biased due to so called length-time bias.128 As in any cross-sectional study, disease (here: 
polyps) with slow growth rate and good prognosis may be more frequently observed than 
aggressive polyps with accelerated growth rate and high malignant potential. This could 
potentially underestimate the CRC risk associated with serrated polyps left in situ and 
bias our conclusion that the CRC risk may not be related to the polyp itself.  
Finally, our results might be affected by the initial classification of the study groups. 
Individuals with both large serrated polyps and advanced adenomas were categorized in 
the advanced adenoma group. This decision was made a priori. The rationale for this 
classification was that an advanced adenoma is a well-known risk factor for CRC, and we 
did not want our estimates of CRC risk in the serrated polyp group to be confounded by 
the presence of these well-established high-risk lesions. As a result, our estimates of CRC 
risk in the serrated polyp group might be too conservative, resulting in a statistically non-
significant difference in CRC incidence in the serrated polyp group compared to the 
general population (NORCCAP control arm, HR 2.5, 95% CI 0.8-7.7). If all individuals 
with large serrated polyps were included in the serrated polyp group (including those with 
concurrent advanced adenomas), the HR for CRC incidence compared to the general 
population would be 3.2 (95% CI 1.3-7.7). The interpretation of the latter result is perhaps 
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more meaningful than the former: Compared to the general population, the HR for CRC 
incidence in the presence of a large serrated polyp is 3.2 (95% CI 1.3-7.7), while the HR 
for CRC incidence in patients with a large serrated polyp without concomitant advanced 
adenoma is 2.5 (95% CI 0.8-7.7). One could argue that the HR of 3.2 is confounded by 
the presence of concomitant advanced adenoma, which may indeed be true, but we show 
that a large serrated polyp is an independent risk factor for CRC when we take 
characteristics of concurrent adenomas into account (Table 5 in paper II: Odds ratio 3.3, 
95% CI 1.3 – 8.6).  
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Colonoscopy is the gold standard for follow-up of a positive CRC screening test. The 
procedure may be uncomfortable or even painful,129 and fear of pain has been reported as 
a barrier to CRC screening recommendation adherence.130 In many countries, 
colonoscopies are performed with sedation and/or analgesia.131,132 Sedation, however, has 
some disadvantages including need for an escort, absenteeism from work, postprocedure 
activity restrictions and sedation-related complications.133,134 Sedation-free colonoscopy 
is without these disadvantages, but to perform unsedated colonoscopy, the proportion of 
painful procedures should be minimal. In paper III, we conducted a randomized trial to 
investigate whether the use of a magnetic endoscopic imaging device (MEI) is beneficial 
to standard colonoscopy using fluoroscopy on demand, which in our institution is 
standard procedure. A number of studies have investigated the effect of the magnetic 
endoscopic imaging device.71,75,76,78,79,135-137 Only one of these studies compared MEI to 
fluoroscopy on demand.79 The other trials compared MEI to no external imaging. 
Pain reported the day after the colonoscopy was our primary outcome in the trial, 
measured on a four point Likert scale by the patient. We dichotomized pain; severe pain 
versus no/slight/moderate pain. We did not find any difference in perceived pain between 
the MEI colonoscopy arm and the standard colonoscopy arm. This is consistent with most 
other MEI trials, but two trials showed lower pain scores among experienced 
endoscopists in favor of the MEI.76,79 However, in one of these trials, this was a subgroup 
analysis.76 In the other trial, the investigators did not detect any difference between the 
study arms when pain was dichotomized into no/slight vs moderate/severe, while they 
found a statistically significant difference between the trial arms when scores from a 
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visual analogue scale (VAS) was used.79 This could be due to the observation that VAS is 
more sensitive instrument than a 4 point Likert scale.138  
We did not find any difference in caecal intubation rate for experienced and 
inexperienced endoscopists combined. In a systematic review, the use of MEI was 
associated with an improved caecal intubation rate, OR 1.92 (95% CI 1.13-3.27).139 This 
result was mostly due to one study in which the caecum intubation rate was as low as 
74% in the control arm.76 In our trial, the caecum intubation rate was 89.5% in the control 
arm which implies that a statistically significant positive effect on caecum intubation rate 
was more difficult to achieve. We would have to include about 3,500 patients in each arm 
to have 80% power to detect a statistically significant difference between the control arm 
with 89% intubation rate and the intervention arm with 91% caecal intubation. We 
detected a statistically significant improvement in caecal intubation rate when MEI-
colonoscopy was compared to standard colonoscopy in inexperienced endoscopists (78% 
vs 56%). This was also found in one other trial.76  The finding indicates that MEI may be 
beneficial in educating new colonoscopists and this conclusion is strengthened by our 
observation that inexperienced endoscopists had less need for assistant from a senior 
colleague in the MEI group (18.5% vs 40.0%, p=0.018).  
We did not detect any difference in caecul intubation time between the study arms. This is 
consistent with findings from five other trials,76-78,135,137 while two studies found shorter 
caecal intubation time with the MEI.75,79 There were no differences between the two arms 
in need for sedation/analgesi in our study. A similar finding was found in three other 
studies. 75-77. Only one study showed that MEI was associated with lower doses of 
sedatives and analgetics.79 
Our trial of the MEI aided colonoscopy has several limitations. First and most important 
is the limitation with respect to generalizability. The MEI was compared to colonoscopy 
with fluoroscopy on demand. Thus, our comparison may not be valid in endoscopy 
centers in which fluoroscopy is unavailable for the colonoscopist. Second, we performed 
our trial in unsedated patients. If all colonoscopies were conducted with sedation, the 
endoscopist would have to pay less attention to performing a painless procedure, and 
caecal intubation failure due to pain would probably be fewer. This might have resulted in 
more equal caecal intubation rates in the two study arms, especially for the inexperience 
colonscopists. Third, our trial was a single center trial, and it was unblinded. Both the 
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endoscopist and the patient may have been affected by the awareness of the “new 
equipment”. Fourth, the feed-back questionnaire from the patient was not anonymous. 
This may have caused a “please the doctor” effect and the patient may have indicated 
better pain scores than what was really the experience. However, this would affect the 
pain scores in both groups to the same extent and should not bias our effect estimate. 
Fifth, we did not state in the protocol the threshold for introducing fluoroscopy in the 
standard colonoscopy arm. Because the trial was unblinded, and the outcome was known 
to the endoscopists, a lower threshold for use of fluoroscopy may have occurred. 
However, in our trial, fluoroscopy was used in 39% of examinations which is in line with 
results from 6 other Norwegian hospitals (25.1% to 60.1% of colonoscopies performed 
with fluoroscopy) in the same period (2007-2010) as our trial.80 Sixth, three of the 
endoscopists in our trial were very experienced, having performed more than 5000 
colonoscopies each. It may be that their endoscopy technique was firmly established and 
less influenced by the new equipment. Finally, there is a limit to what extent one may 
improve one’s colonoscopy performance. If the performance is already excellent, as it 
indeed was for one of the experienced endoscopists in our trial who performed 38% of the 
examinations in the standard group with a caecal intubation rate of 100%, a difference 
between the groups will be difficult to uncover.  
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- We conclude that screening with flexible sigmoidoscopy offered at one occasion 
only reduces both the number of new colorectal cancers and deaths from 
colorectal cancer. We show that also for individuals aged 50-54 years, screening 
with flexible sigmoidoscopy reduces colorectal cancer incidence. 
- The addition of a once only faecal occult blood test to flexible sigmoidoscopy 
screening does not lead to larger reduction in CRC incidence or CRC mortality 
compared to flexible sigmoidoscopy screening only.  
- Individuals with large serrated polyps in the colon or rectum comprise a high-risk 
group for developing colorectal cancer. The risk is increased 4.2-fold compared to 
individuals without polyps at flexible sigmoidoscopy. 
- Individuals with large serrated polyps have a risk of colorectal cancer that is 
comparable to the risk in individuals with advanced adenomas. 
- Large serrated polyps may have an indolent course with minimal growth when 
followed for more than ten years. The polyps may not infer a colorectal cancer 
risk itself, but may be a marker for an excess cancer risk. 
- Colonoscopy with the aid of a magnetic endoscopic imager is not less 
uncomfortable than colonoscopy with fluoroscopy on demand. 
- Magnetic endoscopic imaging may be advantageous for inexperienced 
colonoscopists, leading to higher caecal intubation rate and less need for 
assistance from a senior colleague. 
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After 11 years, a once only flexible sigmoidoscopy examination is protective with respect 
to a diagnosis of colorectal cancer and death from colorectal cancer. It will be interesting 
to follow the NORCCAP cohort, as well as the cohorts in the other flexible 
sigmoidoscopy trials, to assess for how long this protective effect may last.  
For now, it is unknown how often, if ever, a flexible sigmoidoscopy screening 
examination should be repeated. This can only be properly investigated through a 
randomized controlled trial in which individuals are randomized to different screening 
intervals. It is doubtful that such a trial will ever be conducted, even if a roll-out of a 
national screening program with be an ideal scenario for this study. Indeed, comparative 
effectiveness trials in cancer screening programs may be feasible and provide adequately 
powered trials which can answer important research question.140 
Whether CRC screening should or should not be implemented in Norway is a political 
decision which has to take effect of the intervention, complications, costs and available 
resources into account. In Norway, there are no available endoscopy resources which can 
be allocated for screening purposes. The time from referral until appointment for 
colonoscopy has been reported to be 100 weeks at one large Norwegian University 
hospital.141 We should not put ourselves in a position where we screen asymptomatic 
individuals for CRC while examination of individuals with symptoms of CRC is 
postponed due to lack of endoscopic capacity. For this reason, CRC screening should not 
be implemented in Norway at the present time. We should aim at educating more 
endoscopists to be able to introduce CRC screening in Norway. Introduction of the 
Magnetic Imager device may make colonoscopy learning easier. Most cost-effectiveness-
studies show that CRC screening is cost-effective, and some suggest that screening may 
even be cost-saving. This is of great importance for the society, but reducing CRC 
incidence and mortality is of course even more important for the individual. 
If CRC screening should be implemented in Norway, which test to use is also a difficult 
question. We know from randomized controlled trials that FOBT screening with guaiac 
based tests reduce CRC mortality, but not CRC incidence, while flexible sigmoidoscopy 
screening reduces both incidence and mortality. Observational studies consistently shows 
that also colonoscopy reduces CRC incidence and mortality. I do not think that a test that 
does not reduce CRC incidence should be implemented in Norway, and guaiac-based 
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FOBT will probably be abandoned in western countries. Whether the new faecal 
immunochemical occult blood test with their higher sensitivity for colorectal adenomas 
than the guaiac-based tests may also reduce CRC incidence is unknown and should be 
investigated. Finally, new screening tests are evolving and should be compared in 
randomized trials. Recently, the US Food and Drug Administration approved a stool-
DNA test for CRC screening,142 and blood-testing may be valuable in the future.  
To be effective, high compliance with the screening test is necessary and is variable 
between countries and populations.143 Accordingly, a test that is suitable in one 
population may not be the best choice in another. In Norway, we will have sufficient 
information about adherence to different screening tests in the near future, based both on 
attendance rates in the NORCCAP trial, from the screening pilot which compares flexible 
sigmoidoscopy to faecal testing, and from the NordICC trial in which colonoscopy is 
compared to no screening. 
The importance of serrated polyps has just been acknowledged, and much research is 
needed in this area. Some investigators claim that hyperplastic polyps are without 
malignant potential, while others propose them as possible ancestors to SSA/P, which are 
generally acknowledged as cancer precursors. Establishing whether hyperplastic polyps 
may be SSA/P precursors will be of importance when surveillance recommendations are 
given. Further, surveillance intervals are unknown for individuals with serrated polyps. 
This should be investigated through randomized controlled trials with individuals 
randomized to different surveillance intervals.  
We propose that the risk of CRC is as high in individuals with large serrated polyps as in 
those with advanced adenomas. Our results might be hampered by small numbers and 
will have to be confirmed in larger trials. 
Until now, surveillance recommendations are based on separate consideration of 
adenomatous and serrated polyps. As serrated polyps seem to be associated with 
multiplicity of both adenomas and serrated polyps, the total polyp burden may be an 
important consideration of future risk of CRC. This issue is important, may have an 
impact on surveillance recommendations, and should be addressed in future trials. 
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1. The numbers in the parentheses in paper I, table 4 are per 1,000, not per 100. The 
sum of advanced CRC in the screening group is 121, not 120. The sum of 
unclassified CRC in the screening group is 15, not 16. The correct table is 
displayed below. Corrections in bold: 
 
 Screening group  
n (per 1,000) 
Control group 
 Compliers 
n=12,955 
Noncompliers 
n=7,617 
Total 
n=20,572 
 
n=78,220 
Stage Screen detected Post-screen detected    
Localized 29 (2.2) 48 (3.6) 40 (5.4) 117 (5.7) 470 (6.7) 
Advanced 10 (0.8) 49 (3.7) 62 (8.3) 121 (5.9) 562 (7.8) 
Unclassified 2 (0.1) 4 (0.3) 9 (1.2) 15 (0.7) 54 (0.8) 
Total 41 (3.1) 101 (7.6) 111 (15.0) 253 (12.3) 1,086 (15.3) 
 
2. The number needed to screen to save one CRC case is 455 (paper I). 
3. The number needed to screen to save on CRC death is 1667 (paper I). 
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